For over 140 years, the Snellen eye chart and sphero-cylindrical test lenses (the phoropter) have served as the standards for measuring and correcting eyesight in the $50B global vision care industry. Vision correction products based on these crude measurements and delivered through the legacy fulfillment chain provide patients with a limited quality of vision and they have prescription error rates reported to be as high as 50%.

DigitalVision, has developed a patented, next-generation platform for obtaining high-resolution measurements of the visual system, simulating and optimizing corrections, and fulfilling proprietary prescriptions that will provide sharper, clearer eyesight than conventional corrections prescribed with the phortopter and eye chart. Proprietary DigitalVision prescriptions will reduce higher order aberrations that existing vision care products do not correct. The Company’s all-digital fulfillment process will reduce or eliminate prescription errors common in the legacy, non-digital product fulfillment chain.

Compared to the obsolete phoropter (test lenses) and eye chart, the DigitalVision System will establish an improved new standard for the $50 Billion vision care market. The Company intends to position DigitalVision products and services as leading-edge technology differentiators for professionally-owned vision care providers in the increasingly competitive vision care market.